Roche to reduce risk of severe illness for transplant patients with Adenovirus Test

Roche announced the global commercial availability of a quantitative Adenovirus (ADV) Test to help healthcare professionals better monitor and manage severely immunocompromised transplant patients at risk of infections.

“Transplant patients face the risk of significant complications due to adenovirus and other infections,” said Mario Torres, Head of Roche Molecular Diagnostics. “This new addition to our menu provides a more comprehensive solution for laboratories to offer improved monitoring tools so that treatment plans can be adjusted as necessary, providing better patient care.”

Roche’s comprehensive transplant menu now allows critical transplant testing (Cytomegalovirus, Epstein-Barr virus, BK virus and human Adenovirus) on the consolidated cobas 6800/8800 Systems along with other infectious disease tests. The cobas 6800/8800 Systems offer the fastest time-to-results with the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories with improved operating efficiency and the flexibility to adapt to increasing testing demands. The test is available in countries accepting the CE mark.

Enhance your business visibility, optimise reach and differentiate your brand. Health Industry Hub is the only one-stop-hub connecting your business to Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our unique media solutions.

Quantitative Adenovirus Real Time PCR Test

The Adenovirus Test is based on real-time PCR (polymerase chain reaction) and provides quantitative accuracy for detection and quantification of human adenovirus. The test is designed to work in conjunction with the cobas omni Utility Channel reagent to simplify workflow. The assay calibrators are traceable to the World Health Organization (WHO) international standard for adenovirus and reports in International Units Per Millilitre (IU/mL). The test minimizes variability and complexity in testing, offering an alternative to lab-developed tests (LDTs), and reduces workload and alleviates risk for laboratories.

About Adenovirus

Adenovirus is a member of the adenoviridae virus family and has been associated with a range of clinical diseases. Adenovirus spreads most commonly through a cough or a sneeze, direct conjunctival inoculation, faecal-oral spread, or exposure to infected tissue or blood.    

Once infection with human adenovirus occurs, the virus establishes as a latent form and can remain in the body. Most people harbour the virus with no long-term clinical ramifications; however, immunocompromised patients are more likely to develop conjunctivitis, gastroenteritis, hepatitis, myocarditis and pneumonia, all of which can cause complications and organ rejection.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like Effective incentives the key to private health insurance uptake